Navigation Links
Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302
Date:10/11/2011

SEATTLE, Oct. 11, 2011 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the first patients have been treated in the Company's Phase 3 clinical program evaluating OMS302 in intra-ocular lens replacement surgery. OMS302, one of Omeros' proprietary PharmacoSurgery™ products, is added to standard irrigation solution used during cataract and other lens replacement surgery to maintain intraoperative mydriasis (pupil dilation) and reduce postoperative pain and inflammation.

This Phase 3 clinical program is enrolling both cataract surgery and refractive lens exchange patients. Two randomized, double-blind, placebo-controlled, multicenter trials are planned. The first trial is underway in North America, and data are expected in the first quarter of 2012.  Omeros plans to initiate the second trial following discussions with regulators to ensure that data collected meet European expectations for marketing approval. The co-primary endpoints for these trials – maintenance of intraoperative pupil dilation (mydriasis) and reduction of postoperative pain – are the same as those achieved in the recently completed 221-patient Phase 2b trial.

"OMS302 has the potential to represent a significant advance for both ophthalmologic surgeons and their patients," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "The pace of enrollment to date has exceeded our expectations, and we look forward to announcing data from this program early next year."

Omeros' OMS302 Program

OMS302 is Omeros' PharmacoSurgery™ product candidate being developed for use during ophthalmological procedures including cataract and other lens replacement surgery. OMS302 is a proprietary combination of an anti-inflammatory active pharmaceutical ingredient (API) and an API that causes mydriasis (pupil dilation), each with well-known safety and pharmacologic profiles. FDA-approved drugs containing each of these APIs have been used in ophthalmological clinical practice for more than 15 years, and both APIs are contained in generic, FDA-approved drugs.

In a 221-subject Phase 2b clinical trial that evaluated OMS302 in patients undergoing cataract surgery, OMS302 demonstrated clinically meaningful and statistically significant benefits in both prespecified co-primary endpoints – maintenance of intraoperative mydriasis and reduction of pain in the early postoperative period. OMS302 also reduced the frequency of complaints of moderate and severe pain.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding the Company's expectations that data from the first Phase 3 trial of OMS302 will be available during the first quarter of 2012, that Omeros will initiate a second Phase 3 trial of OMS302 following discussions with regulators, that OMS302 could represent a significant advance for significant advance for both ophthalmologic surgeons and their patients, and that Omeros may have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2011. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 Acquisition ... Sciences, Product Development Capabilities in North ... Base . Indegene ( http://www.indegene.com ... the acquisition of Skura Corporation,s life science business. ... adaptive sales enablement technology for life science organizations ...
(Date:4/28/2016)... 2016  While Abbott,s announced purchase of St. ... repair and stent business, healthcare research firm Kalorama ... firmly into patient monitoring.  Kalorama said that patient ... areas, with double-digit growth expected the next 5 ... Remote Patient Monitoring . Abbott Laboratories agreed ...
(Date:4/28/2016)... , April 28, 2016 ... insights on healthcare, announced today that it has been ... Cool Vendor in Life Sciences, 2016, ... 2016.  The report focuses on life-science- oriented analytics, algorithms ... from patients and doctors, confirm medication ingestion, and analyze ...
Breaking Medicine Technology:
(Date:5/2/2016)... , ... May 02, 2016 , ... Eating Recovery ... for eating, mood and anxiety disorders, has rebranded its eating disorder program under a ... residential eating disorder treatment facility on May 16. , To celebrate, ERC Chicago ...
(Date:5/2/2016)... ... 2016 , ... In honor of National Physical Fitness and Sports Month in ... their fitness journey on social media. , The foot care company, which specializes ... product voucher each week during May to one winner. , “Whether the goal is ...
(Date:5/2/2016)... CA (PRWEB) , ... May 02, 2016 , ... Dr. ... provide his patients with same day treatments. In the past, many necessary dental treatments ... or work, along with multiple anesthetic shots and extra chair time. Not only could ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... MedPro Waste ... mail back service. MedPro now offers its mail back service for an all-inclusive ... we are now able to provide service to all of the clients in the ...
(Date:5/2/2016)... NV (PRWEB) , ... May 02, 2016 , ... ... Pharmacy Times, has announced a new Specialty Pharmacy Patient Satisfaction Award that will ... based on the quarterly results from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction ...
Breaking Medicine News(10 mins):